Jupiter Topco LLC Invests $252.67 Million in Xenon Pharmaceuticals Inc. $XENE

Jupiter Topco LLC bought a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the second quarter, Holdings Channel reports. The fund bought 4,186,519 shares of the biopharmaceutical company’s stock, valued at approximately $252,673,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Cinctive Capital Management LP increased its holdings in Xenon Pharmaceuticals by 1.1% in the 4th quarter. Cinctive Capital Management LP now owns 23,317 shares of the biopharmaceutical company’s stock worth $1,045,000 after acquiring an additional 263 shares in the last quarter. State of Wyoming lifted its holdings in Xenon Pharmaceuticals by 30.4% during the fourth quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 350 shares in the last quarter. Quarry LP grew its position in shares of Xenon Pharmaceuticals by 25.0% in the third quarter. Quarry LP now owns 2,500 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 500 shares during the period. Royal Bank of Canada grew its position in shares of Xenon Pharmaceuticals by 0.7% in the first quarter. Royal Bank of Canada now owns 90,387 shares of the biopharmaceutical company’s stock valued at $5,255,000 after purchasing an additional 630 shares during the period. Finally, PNC Financial Services Group Inc. increased its stake in shares of Xenon Pharmaceuticals by 11.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,574 shares of the biopharmaceutical company’s stock worth $295,000 after purchasing an additional 675 shares in the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Stock Up 5.6%

Shares of NASDAQ XENE opened at $63.79 on Thursday. The firm has a 50-day simple moving average of $62.86 and a 200-day simple moving average of $56.22. The stock has a market capitalization of $6.17 billion, a price-to-earnings ratio of -13.46 and a beta of 0.62. Xenon Pharmaceuticals Inc. has a 52 week low of $35.60 and a 52 week high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.05. During the same quarter in the previous year, the company earned ($1.07) earnings per share. As a group, equities research analysts expect that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Needham & Company LLC reduced their price target on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Friday, May 8th. JPMorgan Chase & Co. lifted their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a report on Wednesday, May 27th. Wall Street Zen upgraded Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. HC Wainwright reissued a “buy” rating and set a $74.00 target price on shares of Xenon Pharmaceuticals in a report on Monday, August 10th. Finally, Royal Bank Of Canada decreased their target price on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating on the stock in a research report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $77.13.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, Director Gary Patou sold 1,322 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the transaction, the director directly owned 24,896 shares of the company’s stock, valued at $1,322,973.44. This trade represents a 5.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Gillian Cannon sold 1,190 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the transaction, the director owned 1,455 shares in the company, valued at approximately $77,318.70. This represents a 44.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 12,512 shares of company stock valued at $774,088 in the last ninety days. 2.91% of the stock is currently owned by corporate insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.